{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:00:47Z","timestamp":1791986447990,"version":"4.4.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Due to the ongoing bacillus Calmette-Gu\u00e9rin (BCG) shortage, sequential intravesical gemcitabine and docetaxel has been increasingly used as first-line therapy for high-risk non\u2013muscle-invasive bladder cancer (NMIBC). However, data directly comparing these 2 therapies are lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the outcomes of patients with high-risk NMIBC treated with gemcitabine and docetaxel vs BCG.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study was conducted from January 1, 2011, to December 31, 2021. The median (IQR) duration of follow-up was 23 (12-33) months for patients receiving gemcitabine and docetaxel and 49 (27-79) months for patients receiving BCG. All patients were treated at the University of Iowa tertiary care center. A total of 312 patients with high-risk treatment-naive NMIBC were included; 174 patients were treated with BCG therapy and 138 were treated with gemcitabine and docetaxel therapy.<\/jats:p><\/jats:sec>Exposures<\/jats:title>After undergoing complete transurethral resection of bladder tumor, patients received either sequential intravesical gemcitabine, 1 g, and docetaxel, 37.5 mg, or 1 vial of BCG. Induction treatments were administered once per week for 6 weeks. Maintenance regimens were initiated if the patient was disease free at the first follow-up visit.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was high-grade recurrence-free survival (RFS). Survival probabilities were estimated using the Kaplan-Meier method. Cox regression models were used to evaluate the association of covariates with outcomes. Adverse events were reported using the Common Terminology Criteria for Adverse Events, version 5.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 312 patients, the median (IQR) age was 73 (66-79) years; 255 patients (81.7%) were male and 292 (93.6%) were White. Baseline clinicopathological characteristics such as sex, smoking status, and pretreatment tumor pathology were similar between treatment groups. High-grade RFS estimates were 76% (95% CI, 69%-82%) at 6 months, 71% (95% CI, 64%-78%) at 12 months, and 69% (95% CI, 62%-76%) at 24 months in the BCG group and 92% (95% CI, 86%-95%) at 6 months, 85% (95% CI, 78%-91%) at 12 months, and 81% (95% CI, 72%-87%) at 24 months in the gemcitabine and docetaxel group. Multivariable Cox regression analyses controlled for age, sex, treatment year, and presence of carcinoma in situ revealed that treatment with gemcitabine and docetaxel was associated with better high-grade RFS (hazard ratio, 0.57; 95% CI, 0.33-0.97;P<\/jats:italic>\u2009=\u2009.04) and RFS (hazard ratio, 0.56; 95% CI, 0.34-0.92;P<\/jats:italic>\u2009=\u2009.02) than treatment with BCG. Induction therapy for BCG was associated with greater treatment discontinuation than induction therapy for gemcitabine and docetaxel (9.2% vs 2.9%;P<\/jats:italic>\u2009=\u2009.02).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, gemcitabine and docetaxel therapy was associated with less high-grade disease recurrence and treatment discontinuation than BCG therapy. These findings suggest that, while awaiting results from an ongoing randomized clinical trial during the current BCG shortage, use of gemcitabine and docetaxel can be considered for recommendation in updated practice guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.0849","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T16:02:08Z","timestamp":1677600128000},"page":"e230849","source":"Crossref","is-referenced-by-count":111,"title":["Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the Treatment of Patients With High-Risk Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Ian M.","family":"McElree","sequence":"first","affiliation":[{"name":"Carver College of Medicine, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"issue":"1","key":"zoi230055r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v72.1","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi230055r2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non\u2013muscle invasive bladder cancer: AUA\/SUO guideline.","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"zoi230055r4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/bju.2004.93.issue-4","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"issue":"2","key":"zoi230055r5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer.","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"zoi230055r6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis.","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"zoi230055r7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon a-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"zoi230055r8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"issue":"5","key":"zoi230055r9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2006.05.003","article-title":"Aging and innate immunity.","volume":"24","author":"Solana","year":"2006","journal-title":"Immunity"},{"issue":"1","key":"zoi230055r10","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-180203","article-title":"Multi-perspective tolerance evaluation of bacillus Calmette-Gu\u00e9rin with interferon in the treatment of non\u2013muscle invasive bladder cancer.","volume":"5","author":"Steinberg","year":"2019","journal-title":"Bladder Cancer"},{"key":"zoi230055r11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.urology.2019.10.013","article-title":"Severe infectious complications of intravesical bacillus Calmette-Gu\u00e9rin: a case series of 10 patients.","volume":"137","author":"Yong","year":"2020","journal-title":"Urology"},{"issue":"3","key":"zoi230055r13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage.","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"issue":"3","key":"zoi230055r15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/iju.iju_69_22","article-title":"Tailoring the dose of Moscow strain of intravesical bacillus Calmette-Gu\u00e9rin for Indian patients: a plea for urgent action.","volume":"38","author":"Arora","year":"2022","journal-title":"Indian J Urol"},{"issue":"2","key":"zoi230055r16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/bju.2018.121.issue-2","article-title":"The impact of the global bacille Calmette-Gu\u00e9rin shortage on treatment patterns: population-based data.","volume":"121","author":"Perera","year":"2018","journal-title":"BJU Int"},{"issue":"5","key":"zoi230055r17","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer.","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"zoi230055r18","doi-asserted-by":"publisher","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Gu\u00e9rin (BCG) plus interferon in patients with recurrent non\u2013muscle invasive bladder cancer following a single induction course of BCG.","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol"},{"key":"zoi230055r19","doi-asserted-by":"publisher","author":"McElree","DOI":"10.1097\/JU.0000000000002740"},{"issue":"1","key":"zoi230055r20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients.","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"11","key":"zoi230055r21","doi-asserted-by":"publisher","first-page":"851.e11","DOI":"10.1016\/j.urolonc.2020.07.014","article-title":"Association of bacillus Calmette-Gu\u00e9rin shortages with bladder cancer recurrence: a single-center retrospective study.","volume":"38","author":"Lee","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"zoi230055r22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"6","key":"zoi230055r23","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design.","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"zoi230055r24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"zoi230055r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2020.08.027","article-title":"Unraveling the mechanism of the antitumor activity of bacillus Calmette-Gu\u00e9rin.","volume":"80","author":"Li","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"zoi230055r26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"zoi230055r27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.urology.2022.05.034","article-title":"Association of increased age with decreased response to intravesical instillation of bacille Calmette-Gu\u00e9rin in patients with high-risk non\u2013muscle invasive bladder cancer: retrospective multi-institute results from the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG.","volume":"167","author":"Inoue","year":"2022","journal-title":"Urology"},{"key":"zoi230055r28","doi-asserted-by":"publisher","author":"Chevuru","DOI":"10.1016\/j.urolonc.2022.10.030"},{"issue":"8","key":"zoi230055r29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1159\/000524098","article-title":"Quality of life, efficacy, and safety of sequential intravesical gemcitabine + docetaxel versus BCG for non\u2013muscle invasive urinary bladder cancer: a pilot study.","volume":"106","author":"Pareek","year":"2022","journal-title":"Urol Int"},{"key":"zoi230055r33","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002671.01","article-title":"Pllba-01 final clinical results of pivotal trial of IL-15RaFC superagonist N-803 with BCG in BCG-unresponsive non\u2013muscle invasive bladder cancer (NMIBC) CIS and papillary cohorts.","volume":"207","author":"Chang","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"zoi230055r34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi230055r35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: interim results.","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"zoi230055r38","doi-asserted-by":"publisher","author":"McElree","DOI":"10.1097\/JU.0000000000002848"},{"key":"zoi230055r39","author":"Lobo"},{"key":"zoi230055r3","author":"Chou","year":"2015"},{"key":"zoi230055r12","unstructured":"Flanigan RC, Edney MT, Maddox-Smith A, Harris RG, Evans C, Nagler HM. BCG shortage notice. American Urological Association; 2019. Accessed June 22, 2021. https:\/\/web.archive.org\/web\/20220801145650\/https:\/\/www.auanet.org\/practice-resources\/bcg-info\/bcg-shortage-notice"},{"key":"zoi230055r14","unstructured":"Packiam VT, Gabrielson AT, Kates M. Intravesical gemcitabine and docetaxel for nonmuscle-invasive bladder cancer. American Urological Association. Published online June 1, 2022. Accessed August 11, 2022. https:\/\/web.archive.org\/web\/20220615065645\/https:\/\/www.auanet.org\/membership\/publications-overview\/aua-news\/all-articles\/2022\/june-2022\/intravesical-gemcitabine-and-docetaxel-for-nonmuscle-invasive-bladder-cancer"},{"key":"zoi230055r30","unstructured":"A phase III randomized, open-label, multi-center, global study of durvalumab and bacillus Calmette-Gu\u00e9rin (BCG) administered as combination therapy versus BCG alone in high-risk, BCG naive non\u2013muscle invasive bladder cancer patients. ClinicalTrials.gov identifier: NCT03528694. Updated November 17, 2022. Accessed August 11, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03528694"},{"key":"zoi230055r31","unstructured":"An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Gu\u00e9rin) bladder instillation in BCG-naive patients with high-risk non\u2013muscle invasive bladder cancer. ClinicalTrials.gov identifier: NCT03799835. Updated May 31, 2022. Accessed August 11, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03799835"},{"key":"zoi230055r32","unstructured":"A phase 3, multinational, randomized, open-label, three parallel\u2013arm study of PF-06801591, an anti\u2013PD-1 antibody, in combination with bacillus Calmette-Gu\u00e9rin (BCG induction with or without BCG maintenance) versus BCG (induction and maintenance) in participants with high-risk, BCG-naive non\u2013muscle invasive bladder cancer or PF-06801591 as a single agent in participants with BCG-unresponsive NMIBC. ClinicalTrials.gov identifier: NCT04165317. Updated December 15, 2022. Accessed August 11, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04165317"},{"key":"zoi230055r36","unstructured":"A phase II trial for the use of intravesical gemcitabine and docetaxel (GEMDOCE) in the treatment of BCG naive non\u2013muscle invasive urothelial carcinoma of the bladder. ClinicalTrials.gov identifier: NCT04386746. Updated January 9, 2023. Accessed August 11, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04386746"},{"key":"zoi230055r37","unstructured":"A randomized phase III trial of intravesical BCG versus intravesical docetaxel and gemcitabine treatment in BCG naive high grade non\u2013muscle invasive bladder cancer (BRIDGE). ClinicalTrials.gov identifier: NCT05538663. Updated January 13, 2023. Accessed January 21, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05538663"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801788\/mcelree_2023_oi_230055_1676492671.49354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T23:38:35Z","timestamp":1701992315000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0849","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}